Zinc deficiency and advanced liver fibrosis among HIV and hepatitis C co-infected anti-retroviral naïve persons with alcohol use in Russia.
Adult
Alcohol Drinking
/ adverse effects
Cohort Studies
Coinfection
Cross-Sectional Studies
Female
HIV Infections
/ blood
Hepatitis C, Chronic
/ blood
Humans
Liver Cirrhosis
/ blood
Liver Cirrhosis, Alcoholic
/ blood
Male
Middle Aged
Multivariate Analysis
Prevalence
Russia
/ epidemiology
Young Adult
Zinc
/ blood
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
05
02
2019
accepted:
11
06
2019
entrez:
28
6
2019
pubmed:
28
6
2019
medline:
14
2
2020
Statut:
epublish
Résumé
Liver disease in people living with HIV co-infected with hepatitis C virus is a source of morbidity and mortality in Russia. HIV accelerates liver fibrosis in the setting of HCV co-infection and alcohol use. Zinc deficiency is common among people living with HIV and may be a factor that facilitates the underlying mechanisms of liver fibrosis. We investigated the association between zinc deficiency and advanced liver fibrosis in a cohort of HIV/HCV co-infected persons reporting heavy drinking in Russia. This is a secondary data analysis of baseline data from 204 anti-retroviral treatment naïve HIV/HCV co-infected Russians with heavy drinking that were recruited into a clinical trial of zinc supplementation. The primary outcome of interest in this cross-sectional study was advanced liver fibrosis. Zinc deficiency, the main independent variable, was defined as plasma zinc <0.75 mg/L. Exploratory analyses were performed examining continuous zinc levels and fibrosis scores. Analyses were conducted using multivariable regression models adjusted for potential confounders. The prevalence of advanced liver fibrosis was similar for those with zinc deficiency compared to those with normal zinc levels, (27.7% vs. 23.0%, respectively). We did not detect an association between zinc deficiency and advanced liver fibrosis in the adjusted regression model (aOR: 1.28, 95% CI: 0.62-2.61, p = 0.51) nor in exploratory analyses. In this cohort of Russians with HIV/HCV co-infection, who are anti-retroviral treatment naïve and have heavy alcohol use, we did not detect an association between zinc deficiency or zinc levels and advanced liver fibrosis.
Sections du résumé
BACKGROUND AND AIMS
Liver disease in people living with HIV co-infected with hepatitis C virus is a source of morbidity and mortality in Russia. HIV accelerates liver fibrosis in the setting of HCV co-infection and alcohol use. Zinc deficiency is common among people living with HIV and may be a factor that facilitates the underlying mechanisms of liver fibrosis. We investigated the association between zinc deficiency and advanced liver fibrosis in a cohort of HIV/HCV co-infected persons reporting heavy drinking in Russia.
METHODS
This is a secondary data analysis of baseline data from 204 anti-retroviral treatment naïve HIV/HCV co-infected Russians with heavy drinking that were recruited into a clinical trial of zinc supplementation. The primary outcome of interest in this cross-sectional study was advanced liver fibrosis. Zinc deficiency, the main independent variable, was defined as plasma zinc <0.75 mg/L. Exploratory analyses were performed examining continuous zinc levels and fibrosis scores. Analyses were conducted using multivariable regression models adjusted for potential confounders.
RESULTS
The prevalence of advanced liver fibrosis was similar for those with zinc deficiency compared to those with normal zinc levels, (27.7% vs. 23.0%, respectively). We did not detect an association between zinc deficiency and advanced liver fibrosis in the adjusted regression model (aOR: 1.28, 95% CI: 0.62-2.61, p = 0.51) nor in exploratory analyses.
CONCLUSIONS
In this cohort of Russians with HIV/HCV co-infection, who are anti-retroviral treatment naïve and have heavy alcohol use, we did not detect an association between zinc deficiency or zinc levels and advanced liver fibrosis.
Identifiants
pubmed: 31246992
doi: 10.1371/journal.pone.0218852
pii: PONE-D-19-03534
pmc: PMC6597160
doi:
Substances chimiques
Zinc
J41CSQ7QDS
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0218852Subventions
Organisme : NIAAA NIH HHS
ID : U24 AA020779
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA021989
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI052074
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA020780
Pays : United States
Organisme : NIAAA NIH HHS
ID : U24 AA020778
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI042853
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Clin Sci (Lond). 1992 Dec;83(6):695-700
pubmed: 1336440
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Hepatology. 2007 Jul;46(1):32-6
pubmed: 17567829
Hepatology. 2014 Mar;59(3):767-75
pubmed: 24436062
Nutrition. 1997 Mar;13(3):206-12
pubmed: 9131680
Lancet. 2012 Dec 15;380(9859):2224-60
pubmed: 23245609
PLoS One. 2012;7(11):e50568
pubmed: 23209782
PLoS One. 2012;7(10):e46810
pubmed: 23056462
BMC Infect Dis. 2014;14 Suppl 6:S12
pubmed: 25253447
Clin Gastroenterol Hepatol. 2004 Jun;2(6):469-73
pubmed: 15181614
Gastroenterology. 2018 Apr;154(5):1369-1379
pubmed: 29317276
AIDS. 1992 Jul;6(7):701-8
pubmed: 1503689
Hepatology. 2003 Aug;38(2):518-26
pubmed: 12883497
J Nutr. 2000 May;130(5S Suppl):1421S-3S
pubmed: 10801954
J Viral Hepat. 2008 Mar;15(3):165-72
pubmed: 18233989
J Hepatol. 2014 Nov;61(1 Suppl):S45-57
pubmed: 25086286
Hepatol Med Policy. 2016;1:
pubmed: 28217368
Biol Trace Elem Res. 2017 Sep;179(1):1-7
pubmed: 28093695
Lancet. 1997 Mar 22;349(9055):825-32
pubmed: 9121257
Int J Environ Res Public Health. 2016 Jun 13;13(6):
pubmed: 27304961
J Trace Elem Med Biol. 2014 Oct;28(4):357-63
pubmed: 25260885
J Acquir Immune Defic Syndr. 2006 Dec 1;43(4):475-82
pubmed: 17019373
Curr Opin HIV AIDS. 2014 Jul;9(4):365-70
pubmed: 24840057
Lancet. 2015 Jan 10;385(9963):117-71
pubmed: 25530442
HIV Clin Trials. 2018 Jun;19(3):101-111
pubmed: 29663871
J Viral Hepat. 2015 Jan;22 Suppl 1:1-5
pubmed: 25560838
J Viral Hepat. 2012 Feb;19(2):e184-93
pubmed: 22239518
Clin Gastroenterol Hepatol. 2004 Jun;2(6):463-8
pubmed: 15181613
Hepatology. 1999 Oct;30(4):1054-8
pubmed: 10498659
PLoS One. 2016 Nov 29;11(11):e0166539
pubmed: 27898683
J Nutr. 2017 Apr;147(4):556-562
pubmed: 28228506
Chem Biol Interact. 2003 Jul 25;146(1):89-99
pubmed: 12902156
J Clin Biochem Nutr. 2012 Nov;51(3):178-84
pubmed: 23170044
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207
pubmed: 29074409
J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Dec 1;16(4):272-8
pubmed: 9402074